PATENT CLAIM ANALYSIS

Application Number: 15992529
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "649000"]

Abstract:
The present invention relates to a composition of enantiomers of 3,6,7,7a-tetrahydro-1H-pyrrolo[1,5-a]imidazole-2,5-dione and pharmaceutically acceptable solvates or co-crystals thereof in a certain ratio, a pharmaceutical composition comprising said composition, its use as a medicament and the use of the inventive compositions or pharmaceutical compositions in the treatment and/or prevention of a disease or disorder typically and preferably selected from peripheral sensory neuropathy, preferably peripheral neuropathic pain; seizure; depression; or cognitive impairment.

Claim (Index 1):
A composition comprising (R)-3,6,7,7a-tetrahydro-1H-pyrrolo[1,5-a]imidazole-2,5-dione ((R)-dimiracetam (1)) and (S)-3,6,7,7a-tetrahydro-1H-pyrrolo[1,5-a]imidazole-2,5-dione ((S)-dimiracetam (2)), and/or pharmaceutically acceptable solvates or co-crystals thereof, wherein an enantiomeric excess (ee) of the (R)-dimiracetam (1) is equal to or higher than 33% and lower than or equal to 54%.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 93.0
- Lexical Diversity: 1.47273
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12450944', '13166088', '12891280', '13102705', '14291901']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7214894644949392
- 35 USC 102 Novelty (BERT): 0.526107286327949
- Combined Prediction Score: 0.7019512466782403
- Mean Citation Score: 270.29950599999995
- Max Citation Score: 319.89517
- Similarity Product: 236.42671505703152

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test